Medtech M&A Advisory For The Deals That Don't Make Headlines

Sub-$50M exits in medical devices are more common — and more achievable — than most founders at this stage have been told

We help founders, boards, and investors in the $5M–$50M medtech space understand their exit options, plan and position for the right acquirer, and navigate deals that most M&A advisors don't cover and most founders don't know exist.

Early Exit Roadmap Investor Support

That's the conversation we specialize in. Not in the $100M+ deals that attract traditional bankers, but in the quieter transactions between $2M and $50M where strategic acquirers regularly pay for technology, clearances, and IP that would cost them far more to develop themselves."
Our approach is discreet, analytical, and partnership-driven. We understand the science, the strategy, and the human side of every deal.

Amanda determined our medical device exit strategy and executed it skillfully to a successful outcome. As an investor, significant return on your investment is far from guaranteed but Amanda's ability to see the big picture, rally influential champions to our cause, and compel and negotiate with strategic acquirers resulting in a rewarding exit.
I wouldn't hesitate to recommend her to any medical device startup contemplating an early exit.

Rob Swart, Board Director & Investor

Founders & CEOs

Evaluate M&A appetite, understand what strategic acquirers are actually buying at this deal size, and make the raise-vs-exit decision with full information rather than assumptions.

Learn more

Boards & Directors

Get independent, buyer-informed analysis on exit feasibility, deal structure, and timing so you can fulfill your fiduciary duty with data rather than founder optimism or banker indifference.

Learn more

Investors & Funders

Understand whether exit optionality exists before the next funding decision forces the question with specialist insight into the sub-$50M market that your portfolio companies' leaders don't have.

Learn more

Why Founders & Boards Work With Us

Independent. Experienced. Outcome-focused.

We specialize in smaller, complex medtech deals that traditional bankers overlook — helping startups with limited runway or early clinical traction find the right acquirer and achieve dignified, value-building exits.

Fundraising has stalled or at risk of being diluted

When the end of your financial runway is fast approaching, an early exit may well be your best strategy to realize return on your investment. Or perhaps you're still in a strong position and want to understand your options and strategies to nurture partnerships and potential exits before that changes.

Strategic fit is identified

Timing is crucial in medtech M&A and savvy medical device executives keep a keen eye out for prospective acquirers and windows of opportunity. Often we're asked to help by adding structure, urgency, or competitive tension to already warm acquisition conversations or those that are showing signs of impasse, faltering, or fragility.

Milestones present exit triggers

FDA clearance, a significant clinical result, or a completed pilot study can each represent an inflection point where acquirer interest is highest and your leverage is real. Knowing when that window is open — and when it isn't — matters."

Exit feasibility vs another raise

Gaining structured insight into exit feasibility via an independent, expert assessment provides Boards with the critical intel and framework to address that fork in the road. Knowing whether that next milestone is a multiplier or exit window killer, brings clarity.

As an industrial designer, I've worked with Amanda on several M&A exit projects and can attest to the accuracy of her insights into the market and potential acquirers and how that should inform initial product development or subsequent tweaks.
She recognizes that medical device startups operate on limited budgets and works well with technical teams to get the technology to just where it needs to be to attract buyer interest.

Ryan Lee, Industrial Designer

Early Exit Assessment

An independent, buyer-informed assessment to help founders, boards, and investors determine whether an early exit may be viable and what timing and factors will impact a successful outcome.
Perfect for:Founders and boards who want an independent, accurate assessment to inform next steps.

Start Assessment

Early Exit Roadmap

A structured, execution-ready plan for positioning your company for an early M&A exit when you're confident that's your next best step.It can be initiated on its own or after the Early Exit Assessment service.
Perfect for:Teams that want a clear, buyer-aligned plan to prepare for an early exit that yields optimal success.

Build Your Roadmap

Deal Lead Service

Hands-on leadership of a discreet, targeted exit process — from buyer outreach through deal execution. Sophisticated strategy aligned with early-stage medtech realities produce your best odds of success.
Perfect for:Companies ready to pursue an early exit and want experienced deal leadership to handle the process.

Discuss Deal Support

INVESTORS

We work with venture capital, private equity firms, family offices, and angels seeking to preserve or accelerate value across their medtech portfolios.

Find out how we can help you preserve Portfolio value and optionality

View A Cystic Fibrosis Patient's Journey to Medical Innovation on Beautiful.ai